Lilly Doubles Down on M&A While Musk Comments Sink GE Vernova
Eli Lilly is putting its obesity drug profits to work on deals, and Elon Musk's latest remarks rattled GE Vernova shares heading into the closing bell.
Eli Lilly is riding the obesity drug wave all the way to the dealmaking table. Fresh off blockbuster revenue from its weight-loss treatments, the pharma giant is reportedly channeling that windfall into mergers and acquisitions — a classic move for a company sitting on a mountain of cash and looking to expand its portfolio before competitors catch up.
Meanwhile, shares of GE Vernova took a hit after comments from Elon Musk spooked investors. The energy technology spinoff, which has been a closely watched name in the power and clean-energy space, found itself on the wrong end of market sentiment as Musk's remarks circulated during afternoon trading. When someone with Musk's megaphone says something that touches your sector, traders tend to react first and ask questions later.
Both storylines broke during the final stretch of the trading day — that critical last hour when volume picks up, positions get adjusted, and the market essentially puts a bow on the session. For active investors, moves made in this window can set the tone for the next morning's open, so keeping tabs on late-breaking headlines really does matter.
The broader takeaway here is pretty straightforward: big pharma is flush and hungry for deals, while the clean-energy sector remains sensitive to off-the-cuff commentary from high-profile tech figures. Neither dynamic is new, but both are worth watching as earnings season and policy debates continue to shape market direction.
Continue reading at US Top News and Analysis